BUSINESS
Suraksha Diagnostics: An undervalued growth story
A successful replication of the business model outside the core area will be key to growth
BUSINESS
Canara HSBC Life Insurance IPO: Should you bank on it?
The company has demonstrated strong and consistent profitability over the past two years. However, it is highly dependent on ULIPs and the bancassurance channel
BUSINESS
Is recovery in sight for ZF Commercial Vehicle?
The management remains optimistic about outperforming industry growth, supported by a robust pipeline of new products, stronger aftermarket business, and favourable regulatory developments
BUSINESS
Endurance Tech: Expanding horizons at reasonable valuation
As of FY25, there are about 1.5 crore two-wheelers below 125cc engine capacity without ABS and the company expects to capture at least 25% of this incremental market opportunity
BUSINESS
Seshaasai Technologies IPO: Does it offer a distinctive investment opportunity?
As the fintech space is constantly evolving, execution remains a key determinant for growth
BUSINESS
Subros: Can this auto component stock pick up more speed?
The company is likely to sustain its higher market share in automotive AC components
BUSINESS
Is the fertiliser sector becoming investment worthy?
The latest GST reforms address the key issue of the inverted duty structure
BUSINESS
Krsnaa Diagnostics: Chasing new avenues for growth
Optimistic guidance for FY26; the B2C segment should act as a key growth lever
BUSINESS
Rainbow Children’s Medicare: A high-potential, high-execution play
The Indian healthcare market is experiencing robust growth and the hospital chain is uniquely placed in the paediatric segment
BUSINESS
Global Health: In the pink of health, but growth will come at a price
Demand for high-end healthcare facilities remains strong; however, the company’s valuation appears demanding
BUSINESS
Max Healthcare Q1 FY26: Scaling up amid rich valuations
Max plans to increase its capacity by ~70 percent to reach ~9,000 beds by FY28.
BUSINESS
Apollo Hospital: Growth momentum continues in Q1 FY26
Robust expansion plans in place, with a target of about 4,000 beds in the next 3-4 years
BUSINESS
Bluestone Jewellery and Lifestyle IPO: Will it shine on the bourses?
The company is not profitable at the moment and may continue to make losses in the near term
BUSINESS
KIMS: Mixed performance in Q1, but growth story remains resilient
Future growth to be fuelled by several catalysts, and it could emerge as a stronger player in the healthcare space
BUSINESS
Bosch Q1 FY26: Is the auto ancillary stock racing too fast?
Bosch is planning to strengthen its competitive position in the mobility sector and industrial technology. It is actively adding new components, particularly those catering to EVs and advanced electronics.
BUSINESS
Gabriel India: Primed for growth but priced to perfection
Forays into new segments like sunroof, inorganic and organic strategies show the company’s confidence in the future.
BUSINESS
SJS Enterprises Q1 FY26: On track to meet growth targets
SJS expects to grow at 2x the industry volume in FY26 and maintain a ~26 percent margin level.
BUSINESS
Vijaya Diagnostic: Healthy show continues
The management reiterated its guidance of achieving a top-line growth of around 15 percent and maintaining the current margin profile in FY26.
BUSINESS
Brigade Hotel Ventures: Does the IPO offer a good investment opportunity?
The hotelier’s return ratios are solid and the stock valuation is attractive while part of the IPO money will support growth plans
BUSINESS
Should you decorate your portfolio with this auto ancillary stock?
Driven by the growing demand for aesthetics in premium vehicles, SJS expects to grow at 2x the industry volume in FY26.
BUSINESS
Gabriel India: Unlocking new doors of opportunities
The company recently announced a demerger scheme. This move will transform Gabriel from a single product company into a highly diversified mobility solutions provider.
BUSINESS
Is this agrochemical IPO a good bet?
The company plans to invest in a new dry flowable manufacturing plant to add newer formulations in its portfolio.
BUSINESS
Optimism low on this healthcare stock
Medanta has strong capabilities to leverage its brand image. However, near-term growth looks limited
BUSINESS
How is the health of this healthcare stock?
Timely execution and ramp-up of new projects are crucial for faster growth
